218 related articles for article (PubMed ID: 15485310)
1. Darbepoetin alfa for the treatment of cancer-related anemia: an update.
Pirker R
Expert Rev Anticancer Ther; 2004 Oct; 4(5):735-44. PubMed ID: 15485310
[TBL] [Abstract][Full Text] [Related]
2. Darbepoetin alfa: potential role in managing anemia in cancer patients.
Pirker R; Smith R
Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
[TBL] [Abstract][Full Text] [Related]
3. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
4. Effects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
Folloder J
Oncol Nurs Forum; 2005 Jan; 32(1):81-91. PubMed ID: 15660146
[TBL] [Abstract][Full Text] [Related]
5. Phase III clinical trials with darbepoetin: implications for clinicians.
Glaspy J
Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
[TBL] [Abstract][Full Text] [Related]
6. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
[TBL] [Abstract][Full Text] [Related]
7. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.
Stevenson JG; Natale JJ
Pharmacotherapy; 2007 Mar; 27(3):434-46. PubMed ID: 17316154
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
Glaspy J
Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):29-32. PubMed ID: 16925109
[TBL] [Abstract][Full Text] [Related]
10. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
[TBL] [Abstract][Full Text] [Related]
11. Anemia in cancer patients: significance, epidemiology, and current therapy.
Tchekmedyian NS
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):17-24. PubMed ID: 12380951
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent.
Henry DH
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):9-12. PubMed ID: 12435168
[TBL] [Abstract][Full Text] [Related]
13. Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.
Vansteenkiste J; Wauters I
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1347-55. PubMed ID: 17944560
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
Hesketh PJ; Arena F; Patel D; Austin M; D'Avirro P; Rossi G; Colowick A; Schwartzberg L; Bertoli LF; Cole JT; Demetri G; Dessypris E; Dobbs T; Eisenberg P; Fleischman R; Hall J; Hoffman PC; Laber DA; Leonard J; Lester EP; McCachren S; McMeekin S; Meza L; Miller DS; Nand S; Oliff I; Paroly W; Pawl L; Perez A; Raftopoulos H; Rigas J; Rowland K; Scullin DC; Tezcan H; Waples J; Ward J; Yee LK
Cancer; 2004 Feb; 100(4):859-68. PubMed ID: 14770445
[TBL] [Abstract][Full Text] [Related]
15. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
[TBL] [Abstract][Full Text] [Related]
16. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
Vansteenkiste JF
Cancer Treat Rev; 2006; 32 Suppl 2():S11-5. PubMed ID: 16725268
[TBL] [Abstract][Full Text] [Related]
17. Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.
Vansteenkiste J; Rossi G; Foote M
Expert Opin Biol Ther; 2003 Jun; 3(3):501-8. PubMed ID: 12783618
[TBL] [Abstract][Full Text] [Related]
18. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
19. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency.
Glaspy JA
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):71-7. PubMed ID: 12380957
[TBL] [Abstract][Full Text] [Related]
20. Novel approaches to anemia associated with cancer and chemotherapy.
Kolesar JM
Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S8-11. PubMed ID: 12166035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]